HealthMore in Health→
FDA clears Pfizer and Arvinas breast cancer drug, but uptake questions are already following it
Key Takeaways
- The FDA approved Pfizer and Arvinas’ vepdegestrant on May 1.
- The approval covers patients with a certain form of breast cancer.
- Early coverage characterized the supporting data as underwhelming.
- Questions about how many patients will actually use the drug are already part of the story.
DE
DT Editorial Team··via endpoints.news
